A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

The present disclosure relates to a medical cement composition containing calcium silicate in an amount of less than 20 wt % of a total weight of the composition, with a lithium salt being added thereto. The medical cement composition of the present disclosure has a low compressive strength of 12 MPa or less, after being hardened, for easy removal, excellent stability in storage, and high bioactivity.

The present disclosure relates to a medical cement composition containing calcium silicate in an amount of less than 20 wt % of a total weight of the composition, with a lithium salt being added thereto. The medical cement composition of the present disclosure has a low compressive strength of 12 MPa or less, after being hardened, for easy removal, excellent stability in storage, and high bioactivity.

A dental glass powder includes 15 to 40% by mass of zinc oxide (ZnO), 20 to 55% by mass of silicon oxide (SiO.sub.2), 6 to 20% by mass of aluminum oxide (Al.sub.2O.sub.3), 1 to 13% by mass of calcium oxide (CaO), and 1 to 19% by mass of fluorine (F).

A dental glass powder includes 15 to 40% by mass of zinc oxide (ZnO), 20 to 55% by mass of silicon oxide (SiO.sub.2), 6 to 20% by mass of aluminum oxide (Al.sub.2O.sub.3), 1 to 13% by mass of calcium oxide (CaO), and 1 to 19% by mass of fluorine (F).

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.

Provided is a curable composition comprising a polymerizable monomer (A); spherical particles (B) having an average primary-particle diameter in a range of 230 nm to 1,000 nm; and a polymerization initiator (C), in which 90% or more of individual particles constituting the spherical particles (B) lies in a range of ±5% based on the average primary-particle diameter, and the refractive index of the spherical particles (B) is larger than the refractive index of a polymer of the polymerizable monomer (A). When a 1 mm-thick cured product is formed from the curable composition and the Y value (Yb) of the colored light of the cured product on a black background and the Y value (Yw) of the colored light of the cured product on a white background are each measured using a color difference meter, the ratio therebetween, Yb/Yw, being within a range of 0.2 to 0.5.

Provided is a curable composition comprising a polymerizable monomer (A); spherical particles (B) having an average primary-particle diameter in a range of 230 nm to 1,000 nm; and a polymerization initiator (C), in which 90% or more of individual particles constituting the spherical particles (B) lies in a range of ±5% based on the average primary-particle diameter, and the refractive index of the spherical particles (B) is larger than the refractive index of a polymer of the polymerizable monomer (A). When a 1 mm-thick cured product is formed from the curable composition and the Y value (Yb) of the colored light of the cured product on a black background and the Y value (Yw) of the colored light of the cured product on a white background are each measured using a color difference meter, the ratio therebetween, Yb/Yw, being within a range of 0.2 to 0.5.